ConductScience.org, home

Paper6974593

Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants.

Dennis JW and 3 others. Cancer Res, 1981. Cited by 31 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants. Papers, record 6974593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6974593

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants.
PubMed
Journal
Cancer Res
PubMed
Year
1981
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
0.94
iCite
Revised in PubMed
2003-11-14
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dennis JWJ W
2Donaghue TPT P
3Carlow DAD A
4Kerbel RSR S

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
H-2 AntigensMajor topic
Neoplasms, ExperimentalMajor topic
Animals
Antigens, Neoplasm
Cell Line
Cell Membrane
Cytotoxicity, Immunologic
Endoplasmic Reticulum
Lectins
Mice
Mice, Inbred DBA
Mice, Nude
Microsomes
T-Lymphocytes
Trinitrobenzenes

Source PubMed

Download CSV of topics

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
6764377Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants.Cancer Metastasis Rev1982https://conductscience.org/library/papers/6764377PubMed
6764376Experimental systems for analysis of the malignant phenotype.Cancer Metastasis Rev1982https://conductscience.org/library/papers/6764376PubMed
6607103Differences in the metastatic potential of two sublines of tumor 3LL selected for resistance to natural NK-like effector cells.Cancer Immunol Immunother1983https://conductscience.org/library/papers/6607103PubMed
6237114Identification of asparagine-linked oligosaccharides involved in tumor cell adhesion to laminin and type IV collagen.J Cell Biol1984https://conductscience.org/library/papers/6237114PubMed
3902300Implications of tumor progression on clinical oncology.Clin Exp Metastasis1985https://conductscience.org/library/papers/3902300PubMed
3549035Tumor cell surface carbohydrate and the metastatic phenotype.Cancer Metastasis Rev1987https://conductscience.org/library/papers/3549035PubMed
3081900Oligosaccharide modification by swainsonine treatment inhibits pulmonary colonization by B16-F10 murine melanoma cells.Proc Natl Acad Sci U S A1986https://conductscience.org/library/papers/3081900PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6974593

GET https://conductscience.org/api/papers/v1/6974593/authors